Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BB-1709 in advanced solid tumors
NCT06241898Phase 1Recruiting
- Sponsor
- Bliss Biopharmaceutical
- Start
- Oct 2023
- Primary completion
- Jun 2026
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label trial of BB-1709 in solid tumor (2 arms), sponsored by Bliss Biopharmaceutical. Primary endpoints: Adverse Events at 3 years and Serious Adverse Events at 3 years. Started Oct 2023; status: recruiting.
02
Drugs
BB-1709
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06241898.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06241898.